Summarized by Masters of Longevity from Longevity Technology.
A biotech–AI partnership story about using an AI regulatory platform to accelerate drafting and managing FDA submission materials, helping readers understand the collaboration's role in an upcoming Alzheimer's drug filing.
Key Takeaways
- Annovis is collaborating with an AI regulatory platform to draft and manage New Drug Application documents for buntanetap submission to the FDA.
- Annovis’ internal regulatory and clinical teams will retain full responsibility for verifying and approving every document submitted to the U.S.
- Annovis completed enrollment in its pivotal Phase 3 Alzheimer’s trial with 862 biomarker-confirmed patients, exceeding its original enrollment target.
